PDLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PDL BioPharma, Inc.'s account receivable for the three months ended in Dec. 2013 was $0.3 Mil. PDL BioPharma, Inc.'s revenue for the three months ended in Dec. 2013 was $110.1 Mil. Hence, PDL BioPharma, Inc.'s days sales outstanding for the three months ended in Dec. 2013 was 0.26.
PDL BioPharma, Inc.'s days sales outstanding declined from Dec. 2012 (8.32) to Dec. 2013 (0.26).
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Account receivable can be measured by Days Sales Outstanding.
PDL BioPharma, Inc.'s Days Sales Outstanding for the fiscal year that ended in Dec. 2013 is calculated as
PDL BioPharma, Inc.'s Days Sales Outstanding for the quarter that ended in Dec. 2013 is calculated as:
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PDL BioPharma, Inc. Annual Data
PDL BioPharma, Inc. Quarterly Data